These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21393229)

  • 1. Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei.
    Liu N; Cummings JE; England K; Slayden RA; Tonge PJ
    J Antimicrob Chemother; 2011 Mar; 66(3):564-73. PubMed ID: 21393229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei--Crystal structure, mode of action, and biological activity.
    Rao KN; Lakshminarasimhan A; Joseph S; Lekshmi SU; Lau MS; Takhi M; Sreenivas K; Nathan S; Yusof R; Abd Rahman N; Ramachandra M; Antony T; Subramanya H
    Protein Sci; 2015 May; 24(5):832-40. PubMed ID: 25644789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.
    Neckles C; Eltschkner S; Cummings JE; Hirschbeck M; Daryaee F; Bommineni GR; Zhang Z; Spagnuolo L; Yu W; Davoodi S; Slayden RA; Kisker C; Tonge PJ
    Biochemistry; 2017 Apr; 56(13):1865-1878. PubMed ID: 28225601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei.
    Lu H; Tonge PJ
    Biochemistry; 2010 Feb; 49(6):1281-9. PubMed ID: 20055482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei.
    Cummings JE; Beaupre AJ; Knudson SE; Liu N; Yu W; Neckles C; Wang H; Khanna A; Bommineni GR; Trunck LA; Schweizer HP; Tonge PJ; Slayden RA
    Antimicrob Agents Chemother; 2014; 58(3):1646-51. PubMed ID: 24379198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase.
    Massengo-Tiassé RP; Cronan JE
    J Biol Chem; 2008 Jan; 283(3):1308-1316. PubMed ID: 18032386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy.
    Cummings JE; Kingry LC; Rholl DA; Schweizer HP; Tonge PJ; Slayden RA
    Antimicrob Agents Chemother; 2014; 58(2):931-5. PubMed ID: 24277048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
    Bergler H; Fuchsbichler S; Högenauer G; Turnowsky F
    Eur J Biochem; 1996 Dec; 242(3):689-94. PubMed ID: 9022698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): a target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis.
    Hoang TT; Schweizer HP
    J Bacteriol; 1999 Sep; 181(17):5489-97. PubMed ID: 10464225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli.
    Heath RJ; Rock CO
    J Biol Chem; 1995 Nov; 270(44):26538-42. PubMed ID: 7592873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
    Zhu L; Lin J; Ma J; Cronan JE; Wang H
    Antimicrob Agents Chemother; 2010 Feb; 54(2):689-98. PubMed ID: 19933806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The enoyl-[acyl-carrier-protein] reductases FabI and FabL from Bacillus subtilis.
    Heath RJ; Su N; Murphy CK; Rock CO
    J Biol Chem; 2000 Dec; 275(51):40128-33. PubMed ID: 11007778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escherichia coli enoyl-acyl carrier protein reductase (FabI) supports efficient operation of a functional reversal of β-oxidation cycle.
    Vick JE; Clomburg JM; Blankschien MD; Chou A; Kim S; Gonzalez R
    Appl Environ Microbiol; 2015 Feb; 81(4):1406-16. PubMed ID: 25527535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein EnvM is the NADH-dependent enoyl-ACP reductase (FabI) of Escherichia coli.
    Bergler H; Wallner P; Ebeling A; Leitinger B; Fuchsbichler S; Aschauer H; Kollenz G; Högenauer G; Turnowsky F
    J Biol Chem; 1994 Feb; 269(8):5493-6. PubMed ID: 8119879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methyl-branched fatty acids, inhibitors of enoyl-ACP reductase with antibacterial activity from Streptomyces sp. A251.
    Zheng CJ; Sohn MJ; Chi SW; Kim WG
    J Microbiol Biotechnol; 2010 May; 20(5):875-80. PubMed ID: 20519910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.
    Kitagawa H; Ozawa T; Takahata S; Iida M; Saito J; Yamada M
    J Med Chem; 2007 Sep; 50(19):4710-20. PubMed ID: 17713898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.
    Zheng CJ; Sohn MJ; Lee S; Kim WG
    PLoS One; 2013; 8(11):e78922. PubMed ID: 24312171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
    Yogiara ; Mordukhova EA; Kim D; Kim WG; Hwang JK; Pan JG
    Bioorg Med Chem Lett; 2020 Dec; 30(24):127651. PubMed ID: 33130290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional expression of Francisella tularensis FabH and FabI, potential antibacterial targets.
    Wen L; Chmielowski JN; Bohn KC; Huang JK; Timsina YN; Kodali P; Pathak AK
    Protein Expr Purif; 2009 May; 65(1):83-91. PubMed ID: 19095065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
    Lu H; Tonge PJ
    Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.